You Position: Home > Paper

Progress on development of vaccines against 2019-nCoV

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Journal of Clinical Infectious Diseases
Issue:
1
DOI:
10.3760/cma.j.issn.1674-2397.2021.01.003
Key Word:
冠状病毒属;新型冠状病毒;疫苗;佐剂;免疫效应;Coronavirus;2019-nCoV;Vaccines;Adjuvant;Immunological effect

Abstract´╝Ü Since the outbreak of COVID-19 caused by the 2019-nCoV (SARS-CoV-2), with its high pathogenicity and contagiousness, it has posed a serious threat to global public health security. Up to now, the pathogenesis of 2019-nCoV is unclear, and there is no effective treatment. Vaccine as one of the most effective strategies to prevent virus infection has become a hot area. Based on the current understanding of 2019-nCoV, the development of 2019-nCoV vaccines covers all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, etc. In this review, we focus on the candidate targets of the novel coronavirus, and the types, development status and progress of 2019-nCoV vaccines in order to provide information for further research and prevention.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn